Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Sales and Divestitures (2017 - 2022)

Arcus Biosciences has reported Gains from Sales and Divestitures over the past 6 years, most recently at $500000.0 for Q4 2022.

  • Quarterly results put Gains from Sales and Divestitures at $500000.0 for Q4 2022, up 30.83% from a year ago — trailing twelve months through Dec 2022 was $500000.0 (up 30.83% YoY), and the annual figure for FY2022 was $500000.0, up 30.83%.
  • Gains from Sales and Divestitures for Q4 2022 was $500000.0 at Arcus Biosciences, up from $382183.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for RCUS hit a ceiling of $500000.0 in Q4 2022 and a floor of $6250.0 in Q4 2020.
  • Median Gains from Sales and Divestitures over the past 5 years was $372774.0 (2019), compared with a mean of $255225.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 98.32% in 2020 and later surged 6014.93% in 2021.
  • Arcus Biosciences' Gains from Sales and Divestitures stood at $14918.0 in 2018, then soared by 2398.82% to $372774.0 in 2019, then crashed by 98.32% to $6250.0 in 2020, then surged by 6014.93% to $382183.0 in 2021, then skyrocketed by 30.83% to $500000.0 in 2022.
  • The last three reported values for Gains from Sales and Divestitures were $500000.0 (Q4 2022), $382183.0 (Q4 2021), and $6250.0 (Q4 2020) per Business Quant data.